Open AccessLong-term cardiac outcomes of patients with HER2-positive breast cancer treated in the adjuvant lapatinib and/or trastuzumab Treatment Optimization Trial
Author(s) -
Daniel Eiger,
Noam Pondé,
Dominique Agbor-Tarh,
Alvaro Moreno-Aspitia,
Martine Piccart,
Florentine Hilbers,
Olena Werner,
Saranya Chumsri,
Amylou C. Dueck,
Judith R. Kroep,
Henry Gómez,
István Làng,
Richard J. Rodeheffer,
Michael S. Ewer,
Thomas Suter,
Evandro de Azambuja
Publication year - 2020
Publication title -
british journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.833
H-Index - 236
eISSN - 1532-1827
pISSN - 0007-0920
DOI - 10.1038/s41416-020-0786-x
Subject(s) - medicine , lapatinib , trastuzumab , cardiotoxicity , breast cancer , ejection fraction , hazard ratio , gastroenterology , concomitant , asymptomatic , cancer , surgery , chemotherapy , heart failure , confidence interval
Cardiotoxicity is the most significant adverse event associated with trastuzumab (T), the main component of HER2-positive breast cancer (BC) treatment. Less is known about the cardiotoxicity of dual HER2 blockade with T plus lapatinib (L), although this regimen is used in the metastatic setting.